Jazz Pharmaceuticals/$JAZZ
1D1W1MYTD1Y5YMAX
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
- Ticker
- $JAZZ
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,890
- Headquarters
- Dublin, Ireland
- Website
- www.jazzpharma.com
JAZZ Metrics
BasicAdvanced
$16B
16.99
$14.63
0.36
-
Price and volume
Market cap
$16B
Beta
0.36
52-week high
$265.05
52-week low
$118.19
Average daily volume
734K
Financial strength
Current ratio
1.779
Quick ratio
1.381
Long term debt to equity
70.363
Total debt to equity
91.828
Interest coverage (TTM)
4.67%
Profitability
EBITDA (TTM)
1,927.067
Gross margin (TTM)
91.35%
Net profit margin (TTM)
20.45%
Operating margin (TTM)
26.28%
Effective tax rate (TTM)
-29.31%
Revenue per employee (TTM)
$1,590,000
Management effectiveness
Return on assets (TTM)
6.86%
Return on equity (TTM)
22.11%
Valuation
Price to earnings (TTM)
16.995
Price to revenue (TTM)
3.334
Price to book
3.36
Price to tangible book (TTM)
-15.68
Price to free cash flow (TTM)
11.049
Free cash flow yield (TTM)
9.05%
Free cash flow per share (TTM)
22.508
Growth
Revenue change (TTM)
12.59%
Earnings per share change (TTM)
-320.62%
3-year revenue growth (CAGR)
6.93%
10-year revenue growth (CAGR)
12.64%
3-year earnings per share growth (CAGR)
120.45%
10-year earnings per share growth (CAGR)
9.78%
What the Analysts think about JAZZ
Analyst ratings (Buy, Hold, Sell) for Jazz Pharmaceuticals stock.
JAZZ Financial Performance
Revenues and expenses
JAZZ Earnings Performance
Company profitability
JAZZ News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.